## Brian K Kaspar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8327136/publications.pdf

Version: 2024-02-01

46 papers

6,951 citations

28 h-index 223716 46 g-index

48 all docs 48 docs citations

times ranked

48

9790 citing authors

#	Article	IF	CITATIONS
1	Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. New England Journal of Medicine, 2017, 377, 1713-1722.	13.9	1,642
2	Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nature Biotechnology, 2009, 27, 59-65.	9.4	1,157
3	Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nature Biotechnology, 2011, 29, 824-828.	9.4	696
4	Microglia Induce Motor Neuron Death via the Classical NF-κB Pathway in Amyotrophic Lateral Sclerosis. Neuron, 2014, 81, 1009-1023.	3.8	527
5	The C9orf72 protein interacts with Rab1a and the <scp>ULK</scp> 1 complex to regulate initiation of autophagy. EMBO Journal, 2016, 35, 1656-1676.	3.5	327
6	Improving Single Injection CSF Delivery of AAV9-mediated Gene Therapy for SMA: A Dose–response Study in Mice and Nonhuman Primates. Molecular Therapy, 2015, 23, 477-487.	3.7	217
7	A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy. Molecular Therapy, 2015, 23, 192-201.	3.7	193
8	Therapeutic AAV9-mediated Suppression of Mutant SOD1 Slows Disease Progression and Extends Survival in Models of Inherited ALS. Molecular Therapy, 2013, 21, 2148-2159.	3.7	178
9	Translational profiling identifies a cascade of damage initiated in motor neurons and spreading to glia in mutant SOD1-mediated ALS. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6993-7002.	3.3	165
10	Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19546-19551.	<b>3.</b> 3	140
11	Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6496-E6505.	3.3	139
12	Chronic Oligodendrogenesis and Remyelination after Spinal Cord Injury in Mice and Rats. Journal of Neuroscience, 2015, 35, 1274-1290.	1.7	138
13	Delayed Disease Onset and Extended Survival in the SOD1 <sup>G93A</sup> Rat Model of Amyotrophic Lateral Sclerosis after Suppression of Mutant SOD1 in the Motor Cortex. Journal of Neuroscience, 2014, 34, 15587-15600.	1.7	116
14	Major histocompatibility complex class I molecules protect motor neurons from astrocyte-induced toxicity in amyotrophic lateral sclerosis. Nature Medicine, 2016, 22, 397-403.	15.2	112
15	Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Annals of Neurology, 2005, 57, 773-776.	2.8	108
16	NEUROD1 Instructs Neuronal Conversion in Non-Reactive Astrocytes. Stem Cell Reports, 2017, 8, 1506-1515.	2.3	106
17	SRSF1-dependent nuclear export inhibition of C9ORF72 repeat transcripts prevents neurodegeneration and associated motor deficits. Nature Communications, 2017, 8, 16063.	5.8	106
18	Macrophage Migration Inhibitory Factor as a Chaperone Inhibiting Accumulation of Misfolded SOD1. Neuron, 2015, 86, 218-232.	3.8	98

#	Article	IF	CITATIONS
19	AAV1.NT-3 Gene Therapy for Charcot–Marie–Tooth Neuropathy. Molecular Therapy, 2014, 22, 511-521.	3.7	86
20	Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Molecular Therapy, 2017, 25, 870-879.	3.7	84
21	Transplantation of cerebellar neural stem cells improves motor coordination and neuropathology in Machado-Joseph disease mice. Brain, 2015, 138, 320-335.	3.7	78
22	Electrophysiological biomarkers in spinal muscular atrophy: proof of concept. Annals of Clinical and Translational Neurology, 2014, 1, 34-44.	1.7	55
23	Intravenous Injections in Neonatal Mice. Journal of Visualized Experiments, 2014, , e52037.	0.2	41
24	Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy. Journal of Neuromuscular Diseases, 2015, 2, 185-192.	1.1	34
25	Adeno Associated Virus 9–Based Gene Therapy Delivers a Functional Monocarboxylate Transporter 8, Improving Thyroid Hormone Availability to the Brain of Mct8-Deficient Mice. Thyroid, 2016, 26, 1311-1319.	2.4	34
26	Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in adult rats and pigs. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16046.	1.8	34
27	Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model. Science Advances, 2015, 1, e1500078.	4.7	33
28	An NF-κB - EphrinA5-Dependent Communication between NG2+ Interstitial Cells and Myoblasts Promotes Muscle Growth in Neonates. Developmental Cell, 2016, 36, 215-224.	3.1	33
29	Translating SOD1 Gene Silencing toward the Clinic: A Highly Efficacious, Off-Target-free, and Biomarker-Supported Strategy for fALS. Molecular Therapy - Nucleic Acids, 2018, 12, 75-88.	2.3	33
30	Glia–neuron interactions in neurological diseases: Testing non-cell autonomy in a dish. Brain Research, 2017, 1656, 27-39.	1.1	30
31	Mutations in glycyl-tRNA synthetase impair mitochondrial metabolism in neurons. Human Molecular Genetics, 2018, 27, 2187-2204.	1.4	26
32	MiR-155 deletion reduces ischemia-induced paralysis in an aortic aneurysm repair mouse model: Utility of immunohistochemistry and histopathology in understanding etiology of spinal cord paralysis. Annals of Diagnostic Pathology, 2018, 36, 12-20.	0.6	22
33	Ibuprofen enhances synaptic function and neural progenitors proliferation markers and improves neuropathology and motor coordination in Machado–Joseph disease models. Human Molecular Genetics, 2019, 28, 3691-3703.	1.4	21
34	rAAV Gene Therapy in a Canavan's Disease Mouse Model Reveals Immune Impairments and an Extended Pathology Beyond the Central Nervous System. Molecular Therapy, 2016, 24, 1030-1041.	3.7	18
35	HSPB1 mutations causing hereditary neuropathy in humans disrupt non-cell autonomous protection of motor neurons. Experimental Neurology, 2017, 297, 101-109.	2.0	18
36	Mesenchymal Stem Cells as Trojan Horses for GDNF Delivery in ALS. Molecular Therapy, 2008, 16, 1905-1906.	3.7	15

#	Article	IF	CITATIONS
37	AAV9-MCT8 Delivery at Juvenile Stage Ameliorates Neurological and Behavioral Deficits in a Mouse Model of MCT8-Deficiency. Thyroid, 2022, 32, 849-859.	2.4	14
38	Intracranial delivery of AAV9 gene therapy partially prevents retinal degeneration and visual deficits in CLN6-Batten disease mice. Molecular Therapy - Methods and Clinical Development, 2021, 20, 497-507.	1.8	13
39	Follistatin-induced muscle hypertrophy in aged mice improves neuromuscular junction innervation and function. Neurobiology of Aging, 2021, 104, 32-41.	1.5	11
40	Neurotoxic Astrocytes Directly Converted from Sporadic and Familial ALS Patient Fibroblasts Reveal Signature Diversities and miR-146a Theragnostic Potential in Specific Subtypes. Cells, 2022, 11, 1186.	1.8	11
41	High content analysis in amyotrophic lateral sclerosis. Molecular and Cellular Neurosciences, 2017, 80, 180-191.	1.0	10
42	Conditional deletion of SMN in cell culture identifies functional SMN alleles. Human Molecular Genetics, 2021, 29, 3477-3492.	1.4	9
43	Sox11 is an Activity-Regulated Gene with Dentate-Gyrus-Specific Expression Upon General Neural Activation. Cerebral Cortex, 2020, 30, 3731-3743.	1.6	7
44	Making Sense of Pain: Are Pluripotent Stem Cell–derived Sensory Neurons a New Tool for Studying Pain Mechanisms?. Molecular Therapy, 2014, 22, 1403-1405.	3.7	6
45	Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer's disease. Neurobiology of Disease, 2014, 62, 31-43.	2.1	5
46	Voluntary wheel running with and without follistatin overexpression improves NMJ transmission but not motor unit loss in late life of C57BL/6J mice. Neurobiology of Aging, 2021, 101, 285-296.	1.5	5